Oncolytic Virus Immunotherapy:
Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. Thi...
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
[2022]
|
| Schlagworte: | |
| Online-Zugang: | kostenfrei kostenfrei |
| Zusammenfassung: | Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, "Oncolytic Virus Immunotherapy", summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities |
| Beschreibung: | Titelrückseite: This is a reprint of articles from the Special Issue published online in the open access journal Cancers (ISSN 2072-6694) (available at: www.mdpi.com/journal/cancers/special issues/OVI). |
| Beschreibung: | 1 Online-Ressource |
| ISBN: | 9783036525488 |
| DOI: | 10.3390/books978-3-0365-2548-8 |
Internformat
MARC
| LEADER | 00000nam a22000001c 4500 | ||
|---|---|---|---|
| 001 | BV048390465 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220803s2022 xx o|||| 00||| eng d | ||
| 020 | |a 9783036525488 |9 978-3-0365-2548-8 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-2548-8 |2 doi | |
| 035 | |a (OCoLC)1339074414 | ||
| 035 | |a (DE-599)HEB497452901 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-210 |a DE-521 |a DE-1102 |a DE-1046 |a DE-1028 |a DE-1050 |a DE-573 |a DE-M347 |a DE-92 |a DE-1051 |a DE-898 |a DE-859 |a DE-860 |a DE-1049 |a DE-861 |a DE-863 |a DE-862 |a DE-Re13 |a DE-Y3 |a DE-255 |a DE-Y7 |a DE-Y2 |a DE-70 |a DE-2174 |a DE-127 |a DE-22 |a DE-155 |a DE-91 |a DE-384 |a DE-473 |a DE-19 |a DE-355 |a DE-703 |a DE-20 |a DE-706 |a DE-824 |a DE-29 |a DE-739 | ||
| 084 | |a XD 2815 |0 (DE-625)152549:12921 |2 rvk | ||
| 084 | |a XH 3200 |0 (DE-625)152888:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Oncolytic Virus Immunotherapy |c editors Antonio Marchini, Carolina S. Ilkow, Alan Melcher |
| 264 | 1 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c [2022] | |
| 264 | 2 | |a The Hague |b OAPEN FOUNDATION | |
| 264 | 4 | |c © 2022 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Titelrückseite: This is a reprint of articles from the Special Issue published online in the open access journal Cancers (ISSN 2072-6694) (available at: www.mdpi.com/journal/cancers/special issues/OVI). | ||
| 520 | 3 | |a Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, "Oncolytic Virus Immunotherapy", summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities | |
| 650 | 0 | 7 | |a Viren |0 (DE-588)4063589-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Onkolyse |0 (DE-588)4172588-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Immuntherapie |0 (DE-588)4026640-0 |2 gnd |9 rswk-swf |
| 653 | |a oncolytic viruses | ||
| 653 | |a melanoma | ||
| 653 | |a immunotherapy | ||
| 653 | |a checkpoint inhibitors | ||
| 653 | |a combinatory therapy | ||
| 653 | |a reovirus | ||
| 653 | |a oncolytic virus | ||
| 653 | |a adenovirus | ||
| 653 | |a oncolytic | ||
| 653 | |a virotherapy | ||
| 653 | |a targeting | ||
| 653 | |a immunogenic cell death | ||
| 653 | |a αvβ6 integrin | ||
| 653 | |a oncolytic adenovirus | ||
| 653 | |a cancer immunotherapy | ||
| 653 | |a multi-stage | ||
| 653 | |a immunostimulatory | ||
| 653 | |a arming | ||
| 653 | |a HSV-1 | ||
| 653 | |a clinical trials | ||
| 653 | |a newcastle disease virus | ||
| 653 | |a NDV | ||
| 653 | |a cancer | ||
| 653 | |a immune checkpoint inhibitor | ||
| 653 | |a PD-1 | ||
| 653 | |a PD-L1 | ||
| 653 | |a CTLA-4 | ||
| 653 | |a type I interferon | ||
| 653 | |a herpes simplex virus | ||
| 653 | |a retargeted virus | ||
| 653 | |a tropism retargeting | ||
| 653 | |a tumor | ||
| 653 | |a checkpoint inhibitor | ||
| 653 | |a vaccination | ||
| 653 | |a antigen-agnostic vaccination | ||
| 653 | |a HER2 | ||
| 653 | |a parvovirus | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a combination therapy | ||
| 653 | |a glioblastoma | ||
| 653 | |a class I HLA | ||
| 653 | |a immunosurveillance | ||
| 653 | |a immunoediting | ||
| 653 | |a oncogenic signaling | ||
| 653 | |a RAS | ||
| 653 | |a viral mimicry | ||
| 653 | |a epigenetic silencing | ||
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Onkolyse |0 (DE-588)4172588-8 |D s |
| 689 | 0 | 1 | |a Viren |0 (DE-588)4063589-2 |D s |
| 689 | 0 | 2 | |a Immuntherapie |0 (DE-588)4026640-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Marchini, Antonio |0 (DE-588)122081803 |4 edt | |
| 700 | 1 | |a Ilkow, Carolina S. |4 edt | |
| 700 | 1 | |a Melcher, Alan |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-3-0365-2549-5 |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/81172 |x Verlag |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.3390/books978-3-0365-2548-8 |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-94-OAB | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-033769195 | |
Datensatz im Suchindex
| _version_ | 1822082592341491712 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author2 | Marchini, Antonio Ilkow, Carolina S. Melcher, Alan |
| author2_role | edt edt edt |
| author2_variant | a m am c s i cs csi a m am |
| author_GND | (DE-588)122081803 |
| author_facet | Marchini, Antonio Ilkow, Carolina S. Melcher, Alan |
| building | Verbundindex |
| bvnumber | BV048390465 |
| classification_rvk | XD 2815 XH 3200 |
| collection | ZDB-94-OAB |
| ctrlnum | (OCoLC)1339074414 (DE-599)HEB497452901 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| doi_str_mv | 10.3390/books978-3-0365-2548-8 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a22000001c 4500</leader><controlfield tag="001">BV048390465</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220803s2022 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783036525488</subfield><subfield code="9">978-3-0365-2548-8</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/books978-3-0365-2548-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1339074414</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)HEB497452901</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-210</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-1102</subfield><subfield code="a">DE-1046</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-1050</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-M347</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-1051</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-859</subfield><subfield code="a">DE-860</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-863</subfield><subfield code="a">DE-862</subfield><subfield code="a">DE-Re13</subfield><subfield code="a">DE-Y3</subfield><subfield code="a">DE-255</subfield><subfield code="a">DE-Y7</subfield><subfield code="a">DE-Y2</subfield><subfield code="a">DE-70</subfield><subfield code="a">DE-2174</subfield><subfield code="a">DE-127</subfield><subfield code="a">DE-22</subfield><subfield code="a">DE-155</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-384</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-706</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XD 2815</subfield><subfield code="0">(DE-625)152549:12921</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3200</subfield><subfield code="0">(DE-625)152888:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oncolytic Virus Immunotherapy</subfield><subfield code="c">editors Antonio Marchini, Carolina S. Ilkow, Alan Melcher</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">[2022]</subfield></datafield><datafield tag="264" ind1=" " ind2="2"><subfield code="a">The Hague</subfield><subfield code="b">OAPEN FOUNDATION</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Titelrückseite: This is a reprint of articles from the Special Issue published online in the open access journal Cancers (ISSN 2072-6694) (available at: www.mdpi.com/journal/cancers/special issues/OVI).</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, "Oncolytic Virus Immunotherapy", summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Viren</subfield><subfield code="0">(DE-588)4063589-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Onkolyse</subfield><subfield code="0">(DE-588)4172588-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncolytic viruses</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">combinatory therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">reovirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncolytic virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adenovirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncolytic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">virotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunogenic cell death</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">αvβ6 integrin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncolytic adenovirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multi-stage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunostimulatory</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">arming</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HSV-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical trials</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">newcastle disease virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NDV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-L1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CTLA-4</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">type I interferon</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">herpes simplex virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">retargeted virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tropism retargeting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">checkpoint inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vaccination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antigen-agnostic vaccination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HER2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">parvovirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor microenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">combination therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glioblastoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">class I HLA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunosurveillance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunoediting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncogenic signaling</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RAS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">viral mimicry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epigenetic silencing</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Onkolyse</subfield><subfield code="0">(DE-588)4172588-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Viren</subfield><subfield code="0">(DE-588)4063589-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marchini, Antonio</subfield><subfield code="0">(DE-588)122081803</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ilkow, Carolina S.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Melcher, Alan</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-3-0365-2549-5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://directory.doabooks.org/handle/20.500.12854/81172</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/books978-3-0365-2548-8</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-94-OAB</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033769195</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV048390465 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T20:20:48Z |
| indexdate | 2025-01-23T23:02:50Z |
| institution | BVB |
| isbn | 9783036525488 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033769195 |
| oclc_num | 1339074414 |
| open_access_boolean | 1 |
| owner | DE-12 DE-210 DE-521 DE-1102 DE-1046 DE-1028 DE-1050 DE-573 DE-M347 DE-92 DE-1051 DE-898 DE-BY-UBR DE-859 DE-860 DE-1049 DE-861 DE-863 DE-BY-FWS DE-862 DE-BY-FWS DE-Re13 DE-BY-UBR DE-Y3 DE-255 DE-Y7 DE-Y2 DE-70 DE-2174 DE-127 DE-22 DE-BY-UBG DE-155 DE-BY-UBR DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-703 DE-20 DE-706 DE-824 DE-29 DE-739 |
| owner_facet | DE-12 DE-210 DE-521 DE-1102 DE-1046 DE-1028 DE-1050 DE-573 DE-M347 DE-92 DE-1051 DE-898 DE-BY-UBR DE-859 DE-860 DE-1049 DE-861 DE-863 DE-BY-FWS DE-862 DE-BY-FWS DE-Re13 DE-BY-UBR DE-Y3 DE-255 DE-Y7 DE-Y2 DE-70 DE-2174 DE-127 DE-22 DE-BY-UBG DE-155 DE-BY-UBR DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-703 DE-20 DE-706 DE-824 DE-29 DE-739 |
| physical | 1 Online-Ressource |
| psigel | ZDB-94-OAB |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | marc |
| spelling | Oncolytic Virus Immunotherapy editors Antonio Marchini, Carolina S. Ilkow, Alan Melcher Basel MDPI - Multidisciplinary Digital Publishing Institute [2022] The Hague OAPEN FOUNDATION © 2022 1 Online-Ressource txt rdacontent c rdamedia cr rdacarrier Titelrückseite: This is a reprint of articles from the Special Issue published online in the open access journal Cancers (ISSN 2072-6694) (available at: www.mdpi.com/journal/cancers/special issues/OVI). Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, "Oncolytic Virus Immunotherapy", summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities Viren (DE-588)4063589-2 gnd rswk-swf Onkolyse (DE-588)4172588-8 gnd rswk-swf Immuntherapie (DE-588)4026640-0 gnd rswk-swf oncolytic viruses melanoma immunotherapy checkpoint inhibitors combinatory therapy reovirus oncolytic virus adenovirus oncolytic virotherapy targeting immunogenic cell death αvβ6 integrin oncolytic adenovirus cancer immunotherapy multi-stage immunostimulatory arming HSV-1 clinical trials newcastle disease virus NDV cancer immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 type I interferon herpes simplex virus retargeted virus tropism retargeting tumor checkpoint inhibitor vaccination antigen-agnostic vaccination HER2 parvovirus tumor microenvironment combination therapy glioblastoma class I HLA immunosurveillance immunoediting oncogenic signaling RAS viral mimicry epigenetic silencing (DE-588)4143413-4 Aufsatzsammlung gnd-content Onkolyse (DE-588)4172588-8 s Viren (DE-588)4063589-2 s Immuntherapie (DE-588)4026640-0 s DE-604 Marchini, Antonio (DE-588)122081803 edt Ilkow, Carolina S. edt Melcher, Alan edt Erscheint auch als Druck-Ausgabe, Hardcover 978-3-0365-2549-5 https://directory.doabooks.org/handle/20.500.12854/81172 Verlag kostenfrei Volltext https://doi.org/10.3390/books978-3-0365-2548-8 Verlag kostenfrei Volltext |
| spellingShingle | Oncolytic Virus Immunotherapy Viren (DE-588)4063589-2 gnd Onkolyse (DE-588)4172588-8 gnd Immuntherapie (DE-588)4026640-0 gnd |
| subject_GND | (DE-588)4063589-2 (DE-588)4172588-8 (DE-588)4026640-0 (DE-588)4143413-4 |
| title | Oncolytic Virus Immunotherapy |
| title_auth | Oncolytic Virus Immunotherapy |
| title_exact_search | Oncolytic Virus Immunotherapy |
| title_exact_search_txtP | Oncolytic Virus Immunotherapy |
| title_full | Oncolytic Virus Immunotherapy editors Antonio Marchini, Carolina S. Ilkow, Alan Melcher |
| title_fullStr | Oncolytic Virus Immunotherapy editors Antonio Marchini, Carolina S. Ilkow, Alan Melcher |
| title_full_unstemmed | Oncolytic Virus Immunotherapy editors Antonio Marchini, Carolina S. Ilkow, Alan Melcher |
| title_short | Oncolytic Virus Immunotherapy |
| title_sort | oncolytic virus immunotherapy |
| topic | Viren (DE-588)4063589-2 gnd Onkolyse (DE-588)4172588-8 gnd Immuntherapie (DE-588)4026640-0 gnd |
| topic_facet | Viren Onkolyse Immuntherapie Aufsatzsammlung |
| url | https://directory.doabooks.org/handle/20.500.12854/81172 https://doi.org/10.3390/books978-3-0365-2548-8 |
| work_keys_str_mv | AT marchiniantonio oncolyticvirusimmunotherapy AT ilkowcarolinas oncolyticvirusimmunotherapy AT melcheralan oncolyticvirusimmunotherapy |